PDF(Pubmed)
Abstract：
Companion animal obesity has emerged as a significant veterinary health concern globally, with escalating rates posing challenges for preventive and therapeutic interventions. Obesity not only leads to immediate health problems but also contributes to various comorbidities affecting animal well-being and longevity, with consequent emotional and financial burdens on owners. While past treatment strategies have shown limited success, recent breakthroughs in human medicine present new opportunities for addressing this complex issue in companion animals. Here, we discuss the potential of GLP-1 receptor agonists, specifically semaglutide and tirzepatide, already approved for human use, for addressing companion animal obesity. These drugs, originally developed to treat type 2 diabetes in humans and subsequently repurposed to treat obesity, have demonstrated remarkable weight loss effects in rodents, non-human primates and people. Additionally, newer drug combinations have shown even more promising results in clinical trials. Despite current cost and supply challenges, advancements in oral and/or extended-release formulations and increased production may make these drugs more accessible for veterinary use. Thus, these drugs may have utility in companion animal weight management, and future feasibility studies exploring their efficacy and safety in treating companion animal obesity are warranted.
摘要：
伴侣动物肥胖已成为全球范围内重要的兽医健康问题，随着发病率的不断上升，对预防和治疗干预措施构成了挑战。肥胖不仅会导致直接的健康问题，还会导致各种合并症，影响动物的健康和寿命。随之而来的是业主的情感和经济负担。虽然过去的治疗策略显示出有限的成功，人类医学的最新突破为解决伴侣动物的这一复杂问题提供了新的机会。这里,我们讨论了GLP-1受体激动剂的潜力，特别是司马鲁肽和替瑞哌肽，已经批准人类使用，解决伴侣动物肥胖问题。这些药物,最初开发用于治疗人类2型糖尿病，随后用于治疗肥胖症，在啮齿动物身上表现出显著的减肥效果，非人灵长类动物和人类。此外,新型药物组合在临床试验中显示出更有希望的结果。尽管当前的成本和供应面临挑战，口服和/或缓释制剂的进步和产量的增加可能使这些药物更容易用于兽医使用。因此，这些药物可能在伴侣动物体重管理中具有实用性，未来的可行性研究探索其在治疗伴侣动物肥胖中的有效性和安全性是有必要的。
